铂类敏感型复发性卵巢癌二线化疗疗效观察

目的：评价GP方案、TP方案治疗铂类敏感型复发性卵巢癌的临床疗效。方法：回顾性分析我院2007年6月-2010年9月40例铂类敏感型复发性卵巢癌病例，将患者根据接受化疗方案的不同，分为GP方案化疗组20例和TP方案化疗组20例。GP方案组，吉西他滨1.0g/m2，d1、8；顺铂75mg/m2，d1，21d为1周期；TP方案组，多西他赛75mg/m2，d1；顺铂75mg/m2，d1，21d为1周期。结果：GP方案组近期有效率75.0%，无进展生存期8.9个月，总生存期21.4个月，TP方案组近期有效率70.0%，无进展生存期9.8个月，总生存期23.0个月。2组患者的毒副反应均可耐受，GP方案组血小板减少Ⅲ、Ⅳ度以上的发生率稍高，为25.0%；TP方案组Ⅱ、Ⅲ度脱发、神经毒性的发生率稍高，分别为70.0%，65.0%。结论：两种方案治疗铂类敏感型复发性卵巢癌疗效无统计学差异，毒副反应方面有明显差异，但均可耐受。

Therapeutic effect of second-line chemotherapy for platinum sensitive recurrent ovarian cancers

Objective：To evaluate the clinical effect of GP chemotherapy protocol and TP chemotherapy protocol in treatment of platinum sensitive recurrent ovarian cancers. Methods：We retrospectively analyzed the data of 40 pa-tients with platinum sensitive recurrent ovarian cancers in our hospital form June 2007 to September 2010. According to the difference of chemotherapy protocols,the enrolled patients were divided into 2 groups：GP protocol group and TP protocol group,20 patients in each group. Patients in GP protocol group were given Gemcitabine（1. 0g/m2 ,d1,8 ）and Cisplatin（75mg/m2 ,d1 ）,21d was a period of treatment. Patients in GP protocol group were given Docetaxel（75mg/m2 ,d1 ）and Cisplatin（75mg/m2 ,d1 ）,21d was a period of treatment. Results：For patients in GP protocol group,the short term response rate was 75. 0%,the progression-free-survival period was 8. 9 months,the overall survival peri-od was 21. 4 months. For patients in TP protocol group,the short term response rate was 70. 0%,the progression-free-survival period was 9. 8 months,the overall survival period was 23. 0 months . The toxic and side reactions were tolerable in patients in two groups . The incidence of Ⅲ and Ⅳ grade thrombocytopenia in GP protocol group was 25. 0%,which was a little higher than that in TP protocol group. The incidence of II and III grade alopecia and neuro-toxicity in TP protocol group was 70. 0% and 65. 0%,respectively,which was a little higher than that in GP protocol group. Conclusion：The therapeutic effects of two chemotherapy protocols have no statistically significant difference in treatment of platinum sensitive recurrent ovarian cancer,the toxic and side reactions have statistically significant difference but are tolerable.